Version 1
: Received: 2 August 2023 / Approved: 2 August 2023 / Online: 2 August 2023 (10:02:42 CEST)
Version 2
: Received: 4 August 2023 / Approved: 7 August 2023 / Online: 7 August 2023 (10:03:49 CEST)
Lee, T.S.; Kim, J.Y.; Lee, M.H.; Cho, I.R.; Paik, W.H.; Ryu, J.K.; Kim, Y.-T.; Lee, S.H. Savolitinib: A Promising Targeting Agent for Cancer. Cancers2023, 15, 4708.
Lee, T.S.; Kim, J.Y.; Lee, M.H.; Cho, I.R.; Paik, W.H.; Ryu, J.K.; Kim, Y.-T.; Lee, S.H. Savolitinib: A Promising Targeting Agent for Cancer. Cancers 2023, 15, 4708.
Lee, T.S.; Kim, J.Y.; Lee, M.H.; Cho, I.R.; Paik, W.H.; Ryu, J.K.; Kim, Y.-T.; Lee, S.H. Savolitinib: A Promising Targeting Agent for Cancer. Cancers2023, 15, 4708.
Lee, T.S.; Kim, J.Y.; Lee, M.H.; Cho, I.R.; Paik, W.H.; Ryu, J.K.; Kim, Y.-T.; Lee, S.H. Savolitinib: A Promising Targeting Agent for Cancer. Cancers 2023, 15, 4708.
Abstract
Savolitinib is a highly selective small molecule inhibitor of the mesenchymal epithelial transition factor (MET) tyrosine kinase, primarily developed for the treatment of non-small cell lung cancer (NSCLC) with MET mutations. It is also being investigated as a treatment for breast, head and neck, colorectal, gastric, pancreatic, and other gastrointestinal cancers. In both preclinical and clinical studies, it has demonstrated efficacy in lung, kidney, and stomach cancers. Savolitinib is an oral anti-cancer medication taken as a 600 mg dose once daily. It can be used as a monotherapy in patients with non-small cell lung cancer with MET mutations, and in combination with epidermal growth factor receptor (EGFR) inhibitors for patients who have developed resistance to them. Furthermore, savolitinib has shown positive results in gastric cancer treatment, particularly in combination with docetaxel. As a result, this review aims to validate its efficacy in NSCLC and suggests its potential application in other gastrointestinal cancers, such as pancreatic cancer, based on related research in gastric and renal cancer.
Keywords
Savolitinib; MET-TKI; NSCLC; gastric cancer; renal cell carcinoma; pancreatic cancer
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter: Sang Hyub Lee
Commenter's Conflict of Interests: Author